Prescription painkillers trail only marijuana in abuse rates, report shows
January 10, 2013 by Steven Reinberg, Healthday Reporter in Medications
Rising numbers of people seeking treatment for abuse of these pain drugs, federal officials say.
(HealthDay)—Prescription painkillers are second only to marijuana when it comes to drug abuse, a new government report claims.
Some 22 million Americans have misused prescription painkillers since 2002, according to the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA).
"Any time you have 2 percent of the population using medications like this there is a lot to do, but we are doing a lot with a combination of putting tighter controls on who can get these drugs and public education," said Peter Delany, director of SAMHSA's Center for Behavioral Health Statistics and Quality.
Also, programs such as the Prescription Drug Monitoring Program, which allows doctors to track patients who may be getting painkillers from several sources, has helped get a handle on the problem, he added.
And although the misuse of prescription painkillers has remained fairly constant over the past few years, the real consequence of the problem is the number of people seeking treatment, he said.
"The number of people seeking treatment has come on faster than we thought," Delany said. "The number of people going for treatment for prescription pain drug use has quadrupled from 2004 to 2010 and we have seen a similar increase in what's going on in the emergency room."
In 2009, there were nearly 425,000 emergency department visits involving non-medical or inappropriate use of narcotic painkillers and an estimated 15,600 deaths involving these drugs, according to Dr. Douglas Throckmorton, deputy director for regulatory programs at the Center for Drug Evaluation and Research, which is part of the U.S. Food and Drug Administration.
Some people are concerned that by cracking down on prescription drug abuse, patients who need these pain medications will not be able to get them.
Delany said these concerns must be taken into account as solutions to the problem are crafted and implemented.
On Wednesday, the FDA proposed guidelines for drug makers for testing and evaluating new formulations of these drugs that make them harder to abuse by making them more difficult to tamper with so that abusers can "get high."
In the SAMHSA report, the abuse of narcotic pain relievers varied state to state; pooled data from 2010 and 2011 found that rates of abuse for those aged 12 or older ranged from 3.6 percent in Iowa to 6.4 percent in Oregon.
Seven of the states with the highest rates of narcotic painkiller abuse were in the West—Arizona, Colorado, Idaho, Nevada, New Mexico, Oregon and Washington.
Four of the states with the lowest rates were in the Midwest—Illinois, Iowa, North Dakota and South Dakota—and four were in the South—Florida, Georgia, Maryland and North Carolina, according to the report.
Abuse of these drugs decreased in Kentucky, Louisiana, Massachusetts, Mississippi, New Hampshire, New York, Ohio, Oklahoma, Rhode Island and West Virginia.
The report is based on data from the SAMHSA National Survey on Drug Use and Health, which is a survey of approximately 67,500 people across the United States.
"The public health community has begun to recognize the scope of the epidemic," said Dr. G. Caleb Alexander, co-director of the Center for Drug Safety and Effectiveness at the Johns Hopkins School of Public Health in Baltimore.
Alexander noted that the problem is partially the result of trying to correct another problem, namely, the under-use of narcotic painkillers to manage pain in those who need it.
"One of the factors that has contributed to the epidemic are well-intentioned efforts to try to improve the identification and treatment of patients with pain," he said.
Another factor is the heavy marketing of narcotic painkillers by drug makers, Alexander said. In addition, doctors may be dispensing more pills in a prescription than a patient needs, he added.
"There is abuse and deception in every step of the pipeline, from warehouse robberies to pharmacy holdups down to theft from people's medicine cabinets, so it's a very complex problem," Alexander said.
Another expert, Leo Beletsky, an assistant professor of law and health sciences at Northeastern University School of Law & Bouve College of Health Sciences in Boston, is concerned that government efforts to curb narcotic painkiller abuse may go too far.
"Government officials have championed a number of solutions drawn primarily from the drug enforcement playbook, such as prescription monitoring programs, prosecutions of doctors accused of over-prescribing, and pill mill raids," Beletsky said.
Focusing only on drug supply is short-sighted and dangerous, he noted. "First, it may unduly restrict legitimate patient access to effective pain care and, second, recent data suggests that cutting patients with substance abuse problems off prescription opioid medications may actually push them towards injecting heroin," Beletsky said.
"In other words, as we craft solutions to address prescription drug misuse, we must be extremely careful to avoid causing more harm than good," Beletsky added.
Along with actions to restrict supply, the answer to this problem must include wider access to substance abuse services, drug treatment, counseling and other investments in the scientifically proven ways to address substance abuse, Beletsky explained.
More information: For more on prescription drug abuse, visit the U.S. National Library of Medicine.
Copyright © 2013 HealthDay. All rights reserved.
-
Increase in Internet access parallels growth in prescription drug abuse
May 12, 2011 |
not rated yet |
0
-
Many who first misuse prescription pills get them from friends, family: report
Apr 25, 2012 |
not rated yet |
0
-
Abuse of meds sends as many to ER as illegal drugs
Jun 17, 2010 |
not rated yet |
0
-
Teach prescribers about dangers of long-acting pain meds: FDA
Jul 09, 2012 |
not rated yet |
0
-
Drop in illicit drug use in cities, uptick in prescription drug abuse
Oct 15, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Feds fight morning-after pill age ruling in NY
(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...
Medications
2 hours ago |
not rated yet |
0
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
May 23, 2013 |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
May 23, 2013 |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
First drug to improve heart failure mortality in over a decade
Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...
Heart failure accelerates male 'menopause'
Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...
Hormone levels may provide key to understanding psychological disorders in women
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
Death highest in heart failure patients admitted in January, on Friday, and overnight
Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...
Researchers identify first drug targets in childhood genetic tumor disorder
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
Going live: Immune cell activation in multiple sclerosis
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...